(MedPage Today) — At the American Society of Nephrology (ASN) Kidney Week meeting, an interim analysis of a phase III trial of sibeprenlimab in immunoglobulin A (IgA) nephropathy showed a nearly 50% reduction in proteinuria at 9 months, with favorable…
Source link : https://www.medpagetoday.com/meetingcoverage/kidneyweekvideopearls/118651
Author :
Publish date : 2025-11-21 19:13:00
Copyright for syndicated content belongs to the linked Source.
